CLS-001

N/A

Report date: 2023/12/25 17:37:11

Base Information

Drug NameCLS-001
Drug Alias NameiPS cell-derived corneal endothelial cell substitute (Cellusion )CLS-001CLS001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionCell replacementsCell membrane permeability enhancers
TargetsNot applicable
Therapy Area/IndicationsCorneal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCellusion Inc
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Celregen Therapeutics LtdCellusion Inc
Inactive CompaniesN/A
Active IndicationsCorneal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A